{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:00:40Z","timestamp":1790992840866,"version":"4.1.0"},"reference-count":430,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005780","name":"Chitkara University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.brainres.2025.150047","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:58:24Z","timestamp":1763373504000},"page":"150047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"1870","author":[{"given":"Akhil","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":false,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2025.150047_b0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10048-025-00821-y","article-title":"Multi-target approach to Alzheimer\u2019s disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid- modulating mechanisms","volume":"26","author":"Abbas","year":"2025","journal-title":"Neurogenetics"},{"key":"10.1016\/j.brainres.2025.150047_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0015","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/nri3553","article-title":"The immunobiology of prion diseases","volume":"13","author":"Aguzzi","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1871527322666230306085937","article-title":"Comprehensive Perspective Towards the Management of Proteinopathies by Elucidating Protein Misfolding and Aggregation. CNS Neurol. Disord. - Drug Targets Former","volume":"23","author":"Ahanger","year":"2024","journal-title":"Curr. Drug Targets - CNS Neurol. Disord."},{"key":"10.1016\/j.brainres.2025.150047_b0025","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2102878","article-title":"Microbiota-derived metabolites as drivers of gut\u2013brain communication","volume":"14","author":"Ahmed","year":"2022","journal-title":"Gut Microbes"},{"key":"10.1016\/j.brainres.2025.150047_b0030","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1038\/s41598-017-13839-6","article-title":"Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer\u2019s disease pathology","volume":"7","author":"Ahnaou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/1381612822666151125000300","article-title":"Inflammatory Process in Alzheimer\u2019s and Parkinson\u2019s Diseases: Central Role of Cytokines","volume":"22","author":"Alam","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.brainres.2025.150047_b0040","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.3390\/ijms26125541","article-title":"Beyond Transgenic Mice: Emerging Models and Translational Strategies in Alzheimer\u2019s Disease","volume":"26","author":"Alexandra Lopes","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/jpm15090437","article-title":"Anti-Amyloid Monoclonal Antibodies for Alzheimer\u2019s Disease: Evidence, ARIA Risk, and Precision Patient Selection","volume":"15","author":"Alkhalifa","year":"2025","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.brainres.2025.150047_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.595532","article-title":"Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation","volume":"11","author":"Alquezar","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/antib12020041","article-title":"Recent Trends in Active and Passive Immunotherapies of Alzheimer\u2019s Disease","volume":"12","author":"Alshamrani","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.brainres.2025.150047_b0060","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.brainres.2025.150047_b0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41983-025-00968-3","article-title":"Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer\u2019s disease","volume":"61","author":"Ameen","year":"2025","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"10.1016\/j.brainres.2025.150047_b0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s41983-024-00845-5","article-title":"Unraveling Alzheimer\u2019s: the promise of aducanumab, lecanemab, and donanemab","volume":"60","author":"Ameen","year":"2024","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"10.1016\/j.brainres.2025.150047_b0075","first-page":"030","article-title":"Lecanemab: The advent of biologicals in Alzheimer\u2019s disease, affordability, and clinical relevance","volume":"15","author":"Anil","year":"2025","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113756","article-title":"Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer\u2019s disease and other tauopathies","volume":"343","author":"Annadurai","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0085","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1073\/pnas.0809170106","article-title":"Crystal structure of human prion protein bound to a therapeutic antibody","volume":"106","author":"Antonyuk","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14728222.2020.1738391","article-title":"Alzheimer\u2019s disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation","volume":"24","author":"Anwar","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.brainres.2025.150047_b0095","doi-asserted-by":"crossref","first-page":"15271","DOI":"10.3390\/ijms232315271","article-title":"Blood\u2013Brain Barrier Disruption and Its Involvement in Neurodevelopmental and Neurodegenerative Disorders","volume":"23","author":"Arag\u00f3n-Gonz\u00e1lez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0100","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b0105","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.2174\/0929867331666230727103553","article-title":"Aducanumab in Alzheimer\u2019s Disease: A Critical Update","volume":"31","author":"Ashique","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.brainres.2025.150047_b0110","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/13872877251331640","article-title":"Exploring the efficacy and safety of lecanemab in the management of early Alzheimer\u2019s disease: A systematic review of clinical evidence","volume":"105","author":"Ashmawy","year":"2025","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.brainres.2025.150047_b0115","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.2174\/0929867324666170508110222","article-title":"Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly","volume":"24","author":"Augustyniak","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.brainres.2025.150047_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.brainres.2025.150047_b0125","doi-asserted-by":"crossref","first-page":"25741","DOI":"10.1038\/s41598-024-75204-8","article-title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer\u2019s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","volume":"14","author":"Avgerinos","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2639","article-title":"Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer\u2019s disease","volume":"13","author":"Ayalon","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2025.150047_b0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1871527322666230303114425","article-title":"APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer\u2019s Disease. CNS Neurol. Disord. - Drug Targets Former","volume":"23","author":"Ayyubova","year":"2024","journal-title":"Curr. Drug Targets - CNS Neurol. Disord."},{"key":"10.1016\/j.brainres.2025.150047_b0140","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/jpp\/rgae066","article-title":"Immunotherapy in Alzheimer\u2019s disease: focusing on the efficacy of gantenerumab on amyloid-\u03b2 clearance and cognitive decline","volume":"76","author":"Azargoonjahromi","year":"2024","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.brainres.2025.150047_b0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3109\/08923973.2012.705292","article-title":"The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis","volume":"34","author":"Azizi","year":"2012","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.brainres.2025.150047_b0150","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/biom12101409","article-title":"Alzheimer\u2019s Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound","volume":"12","author":"Baazaoui","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.brainres.2025.150047_b0155","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.3390\/ijms231810970","article-title":"Genetics, Functions, and Clinical Impact of Presenilin-1 (PSEN1) Gene","volume":"23","author":"Bagaria","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0160","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3390\/pharmaceutics13122014","article-title":"Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain","volume":"13","author":"Bajracharya","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.brainres.2025.150047_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00204","article-title":"Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects","volume":"11","author":"Barbier","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1281338","article-title":"Proteostasis and neurodegeneration: a closer look at autophagy in Alzheimer\u2019s disease","volume":"15","author":"Barmaki","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0175","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: Adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b0180","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b0185","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/ijms25020817","article-title":"The Importance of Complement-Mediated Immune Signaling in Alzheimer\u2019s Disease Pathogenesis","volume":"25","author":"Batista","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0190","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0195","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0200","doi-asserted-by":"crossref","first-page":"39671","DOI":"10.1074\/jbc.M402270200","article-title":"PrPSc Binding Antibodies Are Potent Inhibitors of Prion Replication in Cell Lines *","volume":"279","author":"Beringue","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainres.2025.150047_b0205","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2005.02.002","article-title":"Src and Syk kinases: key regulators of phagocytic cell activation","volume":"26","author":"Berton","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0210","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/cells13050449","article-title":"Proximity-Induced Pharmacology for Amyloid-Related Diseases","volume":"13","author":"Bertran-Mostazo","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.150047_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103338","article-title":"A call for better understanding of target engagement in Tau antibody development","volume":"27","author":"Bespalov","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.brainres.2025.150047_b0220","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jconrel.2021.09.010","article-title":"Increasing phagocytosis of microglia by targeting CD33 with liposomes displaying glycan ligands","volume":"338","author":"Bhattacherjee","year":"2021","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.brainres.2025.150047_b0225","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-021-00443-6","article-title":"The CD33 short isoform is a gain-of-function variant that enhances A\u03b21\u201342 phagocytosis in microglia","volume":"16","author":"Bhattacherjee","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b0230","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/bcp.70021","article-title":"Safety and effectiveness of the anti\u2010amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer\u2019s disease: the pharmacovigilance perspective","volume":"91","author":"Bobbins","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.brainres.2025.150047_b0235","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00281-019-00745-4","article-title":"Islet inflammation in type 2 diabetes","volume":"41","author":"B\u00f6ni-Schnetzler","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.brainres.2025.150047_b0240","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3390\/brainsci10110814","article-title":"Do the Bugs in Your Gut Eat Your Memories? Relationship between Gut Microbiota and Alzheimer\u2019s Disease","volume":"10","author":"Borsom","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00401-024-02790-2","article-title":"Inflammatory aspects of Alzheimer\u2019s disease","volume":"148","author":"Botella Lucena","year":"2024","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.brainres.2025.150047_b0250","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0255","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.clinthera.2022.09.008","article-title":"Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease","volume":"44","author":"Boustani","year":"2022","journal-title":"Clin. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b0260","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nn.3435","article-title":"CD33 Alzheimer\u2019s disease locus: altered monocyte function and amyloid biology","volume":"16","author":"Bradshaw","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0265","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p\u2010tau181, p\u2010tau217, and other blood\u2010based Alzheimer\u2019s disease biomarkers in a multi\u2010ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b0270","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/biom13020313","article-title":"The amyloid-beta clearance: from molecular targets to glial and neural cells","volume":"13","author":"Cai","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.brainres.2025.150047_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1465871","article-title":"Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer\u2019s disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"16","author":"Cai","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0285","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1523\/JNEUROSCI.4149-12.2013","article-title":"PrPC controls via protein kinase A the direction of synaptic plasticity in the immature hippocampus","volume":"33","author":"Caiati","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0290","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u201chigh-hanging fruit.","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.brainres.2025.150047_b0295","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","article-title":"Designing antibodies as therapeutics","volume":"185","author":"Carter","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.brainres.2025.150047_b0300","doi-asserted-by":"crossref","first-page":"13049","DOI":"10.3390\/ijms252313049","article-title":"Structures of Oligomeric States of Tau Protein, Amyloid-\u03b2, \u03b1-Synuclein and Prion Protein Implicated in Alzheimer\u2019s Disease, Parkinson\u2019s Disease and Prionopathies","volume":"25","author":"Cehlar","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0305","first-page":"3038","article-title":"Building the value of next-generation platforms: the paradox of diminishing returns","volume":"44","author":"Cennamo","year":"2018","journal-title":"J. Manag."},{"key":"10.1016\/j.brainres.2025.150047_b0310","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vph.2016.11.008","article-title":"The blood brain barrier in Alzheimer\u2019s disease","volume":"89","author":"Chakraborty","year":"2017","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.brainres.2025.150047_b0315","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.brainres.2025.150047_b0320","doi-asserted-by":"crossref","DOI":"10.1177\/1179573517709278","article-title":"Tumor necrosis factor \u03b1 Inhibition for Alzheimer\u2019s Disease","volume":"9","author":"Chang","year":"2017","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.brainres.2025.150047_b0325","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12551-017-0353-8","article-title":"Recent progress on understanding the mechanisms of amyloid nucleation","volume":"10","author":"Chatani","year":"2018","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.brainres.2025.150047_b0330","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.brainres.2025.150047_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2023.105638","article-title":"An immunomodulatory role of Fc receptor \u03b3 chain independent of Fc\u03b3R ligation by IgG in acute neuroinflammation triggered by MPTP intoxication","volume":"171","author":"Chen","year":"2023","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.brainres.2025.150047_b0340","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41398-021-01602-5","article-title":"Staging tau pathology with tau PET in Alzheimer\u2019s disease: a longitudinal study","volume":"11","author":"Chen","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.brainres.2025.150047_b0345","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41420-025-02600-y","article-title":"The multifaceted roles of apolipoprotein E4 in Alzheimer\u2019s disease pathology and potential therapeutic strategies","volume":"11","author":"Chen","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.brainres.2025.150047_b0350","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40035-020-00195-1","article-title":"Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: pathophysiology and therapeutic perspectives","volume":"9","author":"Cheng","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b0355","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00217","article-title":"Amyloid \u03b2-exposed human astrocytes overproduce phospho-Tau and overrelease it within exosomes, effects suppressed by calcilytic NPS 2143\u2014further implications for alzheimer\u2019s Therapy","volume":"11","author":"Chiarini","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0360","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.3390\/ijms21239036","article-title":"Danger-sensing\/patten recognition receptors and neuroinflammation in Alzheimer\u2019s disease","volume":"21","author":"Chiarini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0365","doi-asserted-by":"crossref","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for Alzheimer\u2019s disease: a systematic review","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.brainres.2025.150047_b0370","doi-asserted-by":"crossref","first-page":"10809","DOI":"10.3390\/ijms241310809","article-title":"Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s Diseases and amyotrophic lateral sclerosis","volume":"24","author":"Ciurea","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0375","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/jnr.22392","article-title":"Synapse loss in dementias","volume":"88","author":"Clare","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.brainres.2025.150047_b0380","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/cells13100789","article-title":"Hopping the Hurdle: strategies to enhance the molecular delivery to the brain through the blood\u2013brain barrier","volume":"13","author":"Cogill","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.150047_b0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00401-019-02087-9","article-title":"From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy","volume":"139","author":"Colin","year":"2020","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.brainres.2025.150047_b0390","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087571","article-title":"A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia","volume":"14","author":"Cooper","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0400","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1038\/srep09649","article-title":"Molecular basis for mid-region amyloid-\u03b2 capture by leading Alzheimer\u2019s disease immunotherapies","volume":"5","author":"Crespi","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b0405","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine alzheimer\u2019s disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.brainres.2025.150047_b0410","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.brainres.2025.150047_b0415","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2016.00106","article-title":"Reducing Peripheral Inflammation with Infliximab Reduces Neuroinflammation and Improves Cognition in Rats with Hepatic Encephalopathy","volume":"9","author":"Dadsetan","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0420","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1567205013666160930110551","article-title":"Targeting Tumor Necrosis Factor Alpha for Alzheimer\u2019s Disease","volume":"14","author":"Decourt","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainres.2025.150047_b0425","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.brainres.2025.150047_b0430","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1039\/D0BM01755H","article-title":"Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics","volume":"9","author":"Desale","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0435","doi-asserted-by":"crossref","first-page":"9690","DOI":"10.3390\/ijms25179690","article-title":"Alzheimer\u2019s Disease Pathology and Assistive Nanotheranostic Approaches for Its Therapeutic Interventions","volume":"25","author":"Dey","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0440","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400180","article-title":"Tau Protein and Tauopathies: Exploring Tau Protein\u2013Protein and Microtubule Interactions, Cross-Interactions and Therapeutic Strategies","volume":"19","author":"Di Lorenzo","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.brainres.2025.150047_b0445","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/biomedicines13020279","article-title":"Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer\u2019s Disease Therapeutics","volume":"13","author":"Dias","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.brainres.2025.150047_b0450","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-15-0120","article-title":"Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions","volume":"3","author":"DiLillo","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.brainres.2025.150047_b0455","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14737175.2025.2546868","article-title":"Donanemab for Alzheimer\u2019s disease: from preclinical research to the clinical application","volume":"25","author":"Dodel","year":"2025","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.brainres.2025.150047_b0460","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current Strategies for Brain Drug Delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.brainres.2025.150047_b0465","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-160836","article-title":"Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer\u2019s Disease: The Role of APP","volume":"56","author":"Doran","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.brainres.2025.150047_b0470","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1326784","article-title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","volume":"18","author":"Doran","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0475","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/1567205013666160314150501","article-title":"Molecular Basis of Familial and Sporadic Alzheimer\u2019s Disease","volume":"13","author":"Dorszewska","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainres.2025.150047_b0480","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0485","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease is a clinical-biological construct: An IWG recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0490","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4593","article-title":"Targeting protein aggregation for the treatment of degenerative diseases","volume":"14","author":"Eisele","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.brainres.2025.150047_b0495","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.3390\/ijms241210083","article-title":"Central and Peripheral Inflammation: A Common Factor Causing Addictive and Neurological Disorders and Aging-Related Pathologies","volume":"24","author":"Escobar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0500","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.cell.2024.02.020","article-title":"Type-I-interferon-responsive microglia shape cortical development and behavior","volume":"187","author":"Escoubas","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.brainres.2025.150047_b0505","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s40120-023-00541-1","article-title":"Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer\u2019s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion","volume":"12","author":"Esquer","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b0510","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00401-019-02000-4","article-title":"Evaluation of CD33 as a genetic risk factor for Alzheimer\u2019s disease","volume":"138","author":"Estus","year":"2019","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.brainres.2025.150047_b0515","doi-asserted-by":"crossref","first-page":"42","DOI":"10.33696\/Neurol.5.087","article-title":"Cerebrovascular Dysfunction in Alzheimer\u2019s Disease and Transgenic Rodent Models","volume":"5","author":"Fang","year":"2024","journal-title":"J. Exp. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0520","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2410968","article-title":"Single domain antibody-scFv conjugate targeting amyloid \u03b2 and TfR penetrates the blood\u2013brain barrier and interacts with amyloid \u03b2","volume":"16","author":"Faresj\u00f6","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.brainres.2025.150047_b0525","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5045\/br.2020.55.1.10","article-title":"A general view of CD33+ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy","volume":"55","author":"Fathi","year":"2020","journal-title":"Blood Res."},{"key":"10.1016\/j.brainres.2025.150047_b0530","doi-asserted-by":"crossref","unstructured":"Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P.S., Khan, M.G., Bisht, A.S., Hussain, M.S., 2025a. Amyloid-\u03b2 Clearance with Monoclonal Antibodies: Transforming Alzheimer\u2019s Treatment. Doi: 10.2174\/0113892037362037250205143911.","DOI":"10.2174\/0113892037362037250205143911"},{"key":"10.1016\/j.brainres.2025.150047_b0535","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/0113892037362037250205143911","article-title":"Amyloid-\u03b2 Clearance with Monoclonal Antibodies: Transforming Alzheimer\u2019s Treatment","volume":"26","author":"Fatima","year":"2025","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0540","doi-asserted-by":"crossref","unstructured":"Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P.S., Khan, M.G., Bisht, A.S., Hussain, M.S., 2025c. Amyloid-\u03b2 Clearance with Monoclonal Antibodies: Transforming Alzheimer\u2019s Treatment. Doi: 10.2174\/0113892037362037250205143911.","DOI":"10.2174\/0113892037362037250205143911"},{"key":"10.1016\/j.brainres.2025.150047_b0545","doi-asserted-by":"crossref","unstructured":"Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P.S., Khan, M.G., Bisht, A.S., Hussain, M.S., 2025d. Amyloid-\u03b2 Clearance with Monoclonal Antibodies: Transforming Alzheimer\u2019s Treatment. Doi: 10.2174\/0113892037362037250205143911.","DOI":"10.2174\/0113892037362037250205143911"},{"key":"10.1016\/j.brainres.2025.150047_b0550","doi-asserted-by":"crossref","unstructured":"Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P.S., Khan, M.G., Bisht, A.S., Hussain, M.S., 2025e. Amyloid-\u03b2 Clearance with Monoclonal Antibodies: Transforming Alzheimer\u2019s Treatment. Doi: 10.2174\/0113892037362037250205143911.","DOI":"10.2174\/0113892037362037250205143911"},{"key":"10.1016\/j.brainres.2025.150047_b0555","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70502","article-title":"Early microglial and astrocyte reactivity in preclinical Alzheimer\u2019s disease","volume":"21","author":"Fern\u00e1ndez-Matarrubia","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b0560","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3390\/biom12111676","article-title":"Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer\u2019s Disease and Identifying Promising Drug Targets","volume":"12","author":"Fi\u0161ar","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.brainres.2025.150047_b0565","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00496","article-title":"Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease","volume":"11","author":"Fitzpatrick","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0575","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.brainres.2025.150047_b0580","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/cells13030260","article-title":"Recapitulation of Structure\u2013Function\u2013Regulation of Blood\u2013Brain Barrier under (Patho)Physiological Conditions","volume":"13","author":"Fong","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.150047_b0585","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1002\/alz.13028","article-title":"Preclinical characterization and IND-enabling safety studies for PNT001, an antibody that recognizes cis-pT231 tau","volume":"19","author":"Foster","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b0595","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/ijms26052097","article-title":"Cellular Prion Protein and Amyloid-\u03b2 Oligomers in Alzheimer\u2019s Disease\u2014Are There Connections?","volume":"26","author":"Fu\u0142ek","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0600","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2014.00235","article-title":"New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer\u2019s Disease","volume":"8","author":"Fuller","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0605","doi-asserted-by":"crossref","first-page":"21652","DOI":"10.1074\/jbc.M115.657924","article-title":"Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance versus blocking neuronal uptake*","volume":"290","author":"Funk","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainres.2025.150047_b0610","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.14283\/jpad.2024.163","article-title":"Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer\u2019s Disease","volume":"11","author":"Galpern","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2025.150047_b0615","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fc\u03b3 receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.brainres.2025.150047_b0620","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b0625","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neurobiolaging.2019.01.018","article-title":"Mutation profile of APP, PSEN1, and PSEN2 in Chinese familial Alzheimer\u2019s disease","volume":"77","author":"Gao","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.brainres.2025.150047_b0630","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer\u2019s Disease: Mechanisms and Therapeutic Strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainres.2025.150047_b0635","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1134\/S002689332104004X","article-title":"Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer\u2019s Disease Pathogenesis","volume":"55","author":"Garbuz","year":"2021","journal-title":"Mol. Biol."},{"key":"10.1016\/j.brainres.2025.150047_b0640","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2174\/1570159X22666231017141636","article-title":"Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond","volume":"22","author":"Garmendia","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.brainres.2025.150047_b0645","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/cells11040666","article-title":"Research Progress on Neuroprotection of Insulin-like Growth Factor-1 towards Glutamate-Induced Neurotoxicity","volume":"11","author":"Ge","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.150047_b0650","unstructured":"Genentech, Inc., 2024. A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease (Clinical trial registration No. NCT01998841). clinicaltrials.gov."},{"key":"10.1016\/j.brainres.2025.150047_b0655","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/pharmaceutics15071999","article-title":"Cell-Penetrating and Targeted Peptides Delivery Systems as Potential Pharmaceutical Carriers for Enhanced Delivery across the Blood\u2013Brain Barrier (BBB)","volume":"15","author":"Ghorai","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.brainres.2025.150047_b0660","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.3390\/ijms20194757","article-title":"APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease","volume":"20","author":"Giau","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0665","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","article-title":"Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review","volume":"76","author":"Gibbons","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.dscb.2023.100098","article-title":"The role of PrPc in Alzheimer\u2019s disease related Amyloid-\u03b2 hypothesis: a systematic review","volume":"11","author":"Gomes","year":"2023","journal-title":"Brain Disord."},{"key":"10.1016\/j.brainres.2025.150047_b0675","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.mp.4001508","article-title":"Transgenic animal models of Alzheimer\u2019s disease and related disorders: histopathology, behavior and therapy","volume":"9","author":"G\u00f6tz","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.brainres.2025.150047_b0680","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.neurol.2022.12.006","article-title":"Beyond the amyloid cascade: An update of Alzheimer\u2019s disease pathophysiology","volume":"179","author":"Gouilly","year":"2023","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.brainres.2025.150047_b0685","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b0690","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsaf004","article-title":"A review of public comments submitted to the Centers for Medicare and Medicaid Services in response to the 2022 National Coverage Decision on treatment for Alzheimer\u2019s disease","volume":"12","author":"Greenberg","year":"2025","journal-title":"J. Law Biosci."},{"key":"10.1016\/j.brainres.2025.150047_b0695","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2019.06.010","article-title":"TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer\u2019s Disease","volume":"103","author":"Griciuc","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2025.150047_b0700","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11481-023-10076-9","article-title":"As a Potential Therapeutic Target, C1q Induces Synapse Loss Via Inflammasome-activating Apoptotic and Mitochondria Impairment Mechanisms in Alzheimer\u2019s Disease","volume":"18","author":"Guan","year":"2023","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.brainres.2025.150047_b0705","article-title":"Tau-targeting therapy in Alzheimer\u2019s disease: critical advances and future opportunities. Ageing","volume":"2","author":"Guo","year":"2022","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.brainres.2025.150047_b0710","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer\u2019s disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b0715","article-title":"Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors","volume":"16","author":"Hale","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.brainres.2025.150047_b0720","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00456","article-title":"A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer\u2019s Disease","volume":"11","author":"Hampel","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0725","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.brainres.2025.150047_b0730","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s43856-024-00686-6","article-title":"Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection","volume":"4","author":"Harris","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.brainres.2025.150047_b0735","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/s41598-024-66970-6","article-title":"Targeting soluble amyloid-beta oligomers with a novel nanobody","volume":"14","author":"Haynes","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b0740","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.01154","article-title":"The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer\u2019s Disease","volume":"13","author":"Hillen","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0745","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial","volume":"20","author":"H\u00f6glinger","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0750","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70131","article-title":"Multi-Target Drug Design in Alzheimer\u2019s Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations","volume":"13","author":"Hossain","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.brainres.2025.150047_b0755","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/1040841X.2019.1614904","article-title":"The role of viral infections in the development of autoimmune diseases","volume":"45","author":"Hussein","year":"2019","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.brainres.2025.150047_b0760","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13195-022-01044-1","article-title":"Deletion of Abi3\/Gngt2 influences age-progressive amyloid \u03b2 and tau pathologies in distinctive ways","volume":"14","author":"Ibanez","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b0765","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s42003-021-01851-6","article-title":"Maternal antibodies facilitate Amyloid-\u03b2 clearance by activating Fc-receptor-Syk-mediated phagocytosis","volume":"4","author":"Illouz","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.brainres.2025.150047_b0770","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/alz.12453","article-title":"A critical appraisal of tau-targeting therapies for primary and secondary tauopathies","volume":"18","author":"Imbimbo","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b0775","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/0113816128344571241018154506","article-title":"Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer\u2019s Disease","volume":"31","author":"Inamdar","year":"2025","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.brainres.2025.150047_b0780","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jlb.61.1.6","article-title":"Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades","volume":"61","author":"Isakov","year":"1997","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.brainres.2025.150047_b0785","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12974-020-01820-6","article-title":"The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer\u2019s disease: a longitudinal PET study","volume":"17","author":"Ismail","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainres.2025.150047_b0790","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/biomedicines10071550","article-title":"NMDA and AMPA Receptors at Synapses: Novel Targets for Tau and \u03b1-Synuclein Proteinopathies","volume":"10","author":"Italia","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.brainres.2025.150047_b0795","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1038\/s41598-021-82901-1","article-title":"Astrocytic expression of the Alzheimer\u2019s disease risk allele, ApoE\u03b54, potentiates neuronal tau pathology in multiple preclinical models","volume":"11","author":"Jablonski","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b0800","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"10.1016\/j.brainres.2025.150047_b0805","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b0810","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b0815","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00702-020-02232-9","article-title":"Neuropathological assessment of the Alzheimer spectrum","volume":"127","author":"Jellinger","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.brainres.2025.150047_b0820","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-021-01546-6","article-title":"Current Status of Clinical Trials on Tau Immunotherapies","volume":"81","author":"Ji","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.brainres.2025.150047_b0825","series-title":"Single-Domain Antibodies: Methods and Protocols","first-page":"3","article-title":"Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications","author":"Ji","year":"2022"},{"key":"10.1016\/j.brainres.2025.150047_b0830","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12035-013-8536-1","article-title":"CD33 in Alzheimer\u2019s Disease","volume":"49","author":"Jiang","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2024.103949","article-title":"Lecanemab demonstrates highly selective binding to A\u03b2 protofibrils isolated from Alzheimer\u2019s disease brains","volume":"130","author":"Johannesson","year":"2024","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0840","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00313","article-title":"Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments","volume":"7","author":"Jung","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.brainres.2025.150047_b0845","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41467-024-45627-y","article-title":"Amyloid-\u03b2 aggregates activate peripheral monocytes in mild cognitive impairment","volume":"15","author":"Juul-Madsen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b0850","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/pharmaceutics16111443","article-title":"Designed Cell-Penetrating Peptide Constructs for Inhibition of Pathogenic Protein Self-Assembly","volume":"16","author":"Kalmouni","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.brainres.2025.150047_b0855","article-title":"Unraveling the tau puzzle: a review of mechanistic targets and therapeutic interventions to prevent tau pathology in Alzheimer\u2019s disease. Ageing","volume":"3","author":"Kammula","year":"2023","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.brainres.2025.150047_b0860","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01139","article-title":"The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration","volume":"10","author":"Katsinelos","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b0865","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10787-019-00580-x","article-title":"Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer\u2019s disease","volume":"27","author":"Kaur","year":"2019","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.brainres.2025.150047_b0870","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s12035-022-03164-z","article-title":"Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders","volume":"60","author":"Kaur","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b0875","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1523\/JNEUROSCI.2620-14.2015","article-title":"Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Deficiency Attenuates Phagocytic Activities of Microglia and Exacerbates Ischemic Damage in Experimental Stroke","volume":"35","author":"Kawabori","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b0880","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-2-18","article-title":"Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers","volume":"2","author":"Kayed","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b0885","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.70046","article-title":"Alzheimer\u2019s Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches","volume":"103","author":"Kelliny","year":"2025","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.brainres.2025.150047_b0890","doi-asserted-by":"crossref","first-page":"17449","DOI":"10.1074\/jbc.M117.807396","article-title":"Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody","volume":"292","author":"Kenniston","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainres.2025.150047_b0895","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.3390\/ijms24097960","article-title":"Autoimmune Neuroinflammatory Diseases: Role of Interleukins","volume":"24","author":"Khan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0900","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b0905","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41586-025-08852-z","article-title":"Immune checkpoint TIM-3 regulates microglia and Alzheimer\u2019s disease","volume":"641","author":"Kimura","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.brainres.2025.150047_b0910","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00401-016-1612-7","article-title":"The epigenome in Alzheimer\u2019s disease: current state and approaches for a new path to gene discovery and understanding disease mechanism","volume":"132","author":"Klein","year":"2016","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.brainres.2025.150047_b0915","doi-asserted-by":"crossref","first-page":"14726","DOI":"10.1038\/ncomms14726","article-title":"Pre-plaque conformational changes in Alzheimer\u2019s disease-linked A\u03b2 and APP","volume":"8","author":"Klementieva","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b0920","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b0925","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau\u2013tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b0930","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3233\/JAD-2011-110230","article-title":"Anti-Amyloid-\u03b2 Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer\u2019s Disease Mouse Model","volume":"27","author":"Kou","year":"2011","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.brainres.2025.150047_b0935","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/ijms17020185","article-title":"Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos","volume":"17","author":"Kristensen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b0940","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12035-021-02611-7","article-title":"Implications of Phosphoinositide 3-Kinase-Akt (PI3K-Akt) Pathway in the Pathogenesis of Alzheimer\u2019s Disease","volume":"59","author":"Kumar","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b0945","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12782","article-title":"Dysfunction of the blood\u2013brain barrier in Alzheimer\u2019s disease: Evidence from human studies","volume":"48","author":"Kurz","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b0950","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","article-title":"Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET","volume":"96","author":"La Joie","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2025.150047_b0955","first-page":"525","article-title":"Structural Basis of C-terminal \u03b2-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer\u2019s Disease","volume":"421","author":"La Porte","year":"2012","journal-title":"J. Mol. Biol., Amyloid Structure, Function, and Molecular Mechanisms (Part II)"},{"key":"10.1016\/j.brainres.2025.150047_b0960","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jnnp-2017-316201","article-title":"Peripheral inflammatory markers in Alzheimer\u2019s disease: a systematic review and meta-analysis of 175 studies","volume":"88","author":"Lai","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.brainres.2025.150047_b0965","doi-asserted-by":"crossref","unstructured":"Lanoisel\u00e9e, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., Quillard-Muraine, M., Sayette, V. de la, Boutoleau-Bretonniere, C., Etcharry-Bouyx, F., Chauvir\u00e9, V., Sarazin, M., Ber, I. le, Epelbaum, S., Jonveaux, T., Rouaud, O., Ceccaldi, M., F\u00e9lician, O., Godefroy, O., Formaglio, M., Croisile, B., Auriacombe, S., Chamard, L., Vincent, J.-L., Sauv\u00e9e, M., Marelli-Tosi, C., Gabelle, A., Ozsancak, C., Pariente, J., Paquet, C., Hannequin, D., Campion, D., Project, collaborators of the C.-M., 2017. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLOS Med. 14, e1002270. Doi: 10.1371\/journal.pmed.1002270.","DOI":"10.1371\/journal.pmed.1002270"},{"key":"10.1016\/j.brainres.2025.150047_b0970","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1091581817740873","article-title":"Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases","volume":"36","author":"Lansita","year":"2017","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.brainres.2025.150047_b0975","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40478-023-01526-9","article-title":"Roles of neuropathology-associated reactive astrocytes: a systematic review","volume":"11","author":"Lawrence","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b0980","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1357-2725(98)00108-3","article-title":"Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis","volume":"31","author":"Lennartz","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.brainres.2025.150047_b0985","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.brainres.2025.150047_b0990","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrd.2017.155","article-title":"Tau-based therapies in neurodegeneration: opportunities and challenges","volume":"16","author":"Li","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.brainres.2025.150047_b0995","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.3390\/ijms25105169","article-title":"Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer\u2019s Disease","volume":"25","author":"Li","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1000","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/antib5030019","article-title":"Antibody Aggregation: Insights from Sequence and Structure","volume":"5","author":"Li","year":"2016","journal-title":"Antibodies"},{"key":"10.1016\/j.brainres.2025.150047_b1005","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/ggi.13488","article-title":"Dementia and Alzheimer\u2019s disease risks in patients with autoimmune disorders","volume":"18","author":"Li","year":"2018","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.brainres.2025.150047_b1010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neuroscience.2021.11.001","article-title":"Etanercept Reduces Neuron Injury and Neuroinflammation via Inactivating c-Jun N-terminal Kinase and Nuclear Factor-\u03baB Pathways in Alzheimer\u2019s Disease: An In Vitro and In Vivo Investigation","volume":"484","author":"Li","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainres.2025.150047_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115218","article-title":"TREM2: Potential therapeutic targeting of microglia for Alzheimer\u2019s disease","volume":"165","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.brainres.2025.150047_b1020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jad.2025.01.022","article-title":"Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data","volume":"374","author":"Li","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.brainres.2025.150047_b1025","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","article-title":"Anti-ApoE Antibody Given after Plaque Onset Decreases A\u03b2 Accumulation and Improves Brain Function in a Mouse Model of A\u03b2 Amyloidosis","volume":"34","author":"Liao","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1030","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI96429","article-title":"Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation","volume":"128","author":"Liao","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.brainres.2025.150047_b1035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","article-title":"Functional morphology of the blood\u2013brain barrier in health and disease","volume":"135","author":"Liebner","year":"2018","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.brainres.2025.150047_b1045","doi-asserted-by":"crossref","first-page":"22752","DOI":"10.1021\/acsnano.4c06851","article-title":"Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides","volume":"18","author":"Lin","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.brainres.2025.150047_b1050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40120-021-00282-z","article-title":"The Development of Pharmacological Therapies for Alzheimer\u2019s Disease","volume":"10","author":"Lin","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b1055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/glia.22359","article-title":"Microglial activatory (immunoreceptor tyrosine-based activation motif)- and inhibitory (immunoreceptor tyrosine-based inhibition motif)-signaling receptors for recognition of the neuronal glycocalyx","volume":"61","author":"Linnartz","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.brainres.2025.150047_b1060","article-title":"Microglial Immunoreceptor Tyrosine-Based Activation and Inhibition Motif Signaling in Neuroinflammation","volume":"2010","author":"Linnartz","year":"2010","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573256","article-title":"Protective Functions of Reactive Astrocytes Following Central Nervous System Insult","volume":"11","author":"Linnerbauer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b1070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12551-017-0289-z","article-title":"Monomer-dependent secondary nucleation in amyloid formation","volume":"9","author":"Linse","year":"2017","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.brainres.2025.150047_b1075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b1080","doi-asserted-by":"crossref","first-page":"558","DOI":"10.14283\/jpad.2024.61","article-title":"Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials","volume":"11","author":"Liu","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1085","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.729706","article-title":"Clearance Systems in the Brain, From Structure to Function","volume":"15","author":"Liu","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-Engineering for Modulated Effector Functions\u2014Improving Antibodies for Cancer Treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.brainres.2025.150047_b1095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12035-014-8694-9","article-title":"Clearance of Amyloid-Beta in Alzheimer\u2019s Disease: Shifting the Action Site from Center to Periphery","volume":"51","author":"Liu","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b1100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12959","article-title":"Current and emerging avenues for Alzheimer\u2019s disease drug targets","volume":"286","author":"Loera-Valencia","year":"2019","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.brainres.2025.150047_b1105","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2174\/1567205016666191210094435","article-title":"Role of Cdk5 in Amyloid-beta Pathology of Alzheimer\u2019s Disease","volume":"16","author":"Lu","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainres.2025.150047_b1110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/1568007054038210","article-title":"Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimer\u2019s Disease","volume":"4","author":"Lue","year":"2005","journal-title":"Curr. Drug Targets - CNS Neurol. Disord."},{"key":"10.1016\/j.brainres.2025.150047_b1115","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1021\/jm3008618","article-title":"Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4\u2013Associated Neuropathology","volume":"55","author":"Mahley","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2025.150047_b1120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13024-015-0048-1","article-title":"Genetics ignite focus on microglial inflammation in Alzheimer\u2019s disease","volume":"10","author":"Malik","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b1125","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/ph18010104","article-title":"Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies","volume":"18","author":"Mallick","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.brainres.2025.150047_b1130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00401-018-1866-3","article-title":"Patterns and severity of vascular amyloid in Alzheimer\u2019s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer\u2019s disease","volume":"136","author":"Mann","year":"2018","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.brainres.2025.150047_b1135","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-025-05263-z","article-title":"Boosting Brain Clean-Up: Can Targeting UPS Genes Offer Neuroprotection?","author":"Mannan","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b1140","doi-asserted-by":"crossref","unstructured":"Mavoungou, C., Zimmerman, K.S., 2013. Immunotherapy with Anti-A\u03b2 Monoclonal Antibodies in Alzheimer\u2019s Disease: A Critical Review on the Molecules in the Pipelines with Regulatory Considerations, in: Frontiers in Clinical Drug Research - Alzheimer Disorders: Volume 1. Bentham Science Publishers, pp. 3\u201385.","DOI":"10.2174\/9781608057221113010003"},{"key":"10.1016\/j.brainres.2025.150047_b1145","first-page":"22","article-title":"Innate Immunity in Alzheimer\u2019s Disease","volume":"1","author":"McGeer","year":"2001","journal-title":"Mol. Interv."},{"key":"10.1016\/j.brainres.2025.150047_b1150","first-page":"1805","article-title":"Microglia in Alzheimer\u2019s Disease: Exploring How Genetics and Phenotype Influence Risk. J. Mol. Biol","volume":"431","author":"McQuade","year":"2019","journal-title":"Dementia, Brain Disorders and Molecular Mechanisms"},{"key":"10.1016\/j.brainres.2025.150047_b1155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13195-019-0553-5","article-title":"Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A\u03b2","volume":"11","author":"Meilandt","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b1160","first-page":"1","article-title":"Role of CXCL10 in central nervous system inflammation","volume":"6","author":"Michlmayr","year":"2014","journal-title":"Int. J. Interferon Cytokine Mediat. Res."},{"key":"10.1016\/j.brainres.2025.150047_b1165","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3390\/ijms15034671","article-title":"Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction","volume":"15","author":"Mietelska-Porowska","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1170","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/srep01302","article-title":"Bapineuzumab captures the N-terminus of the Alzheimer\u2019s disease amyloid-beta peptide in a helical conformation","volume":"3","author":"Miles","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b1175","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/biomedicines9091126","article-title":"Alzheimer\u2019s Disease: A Molecular View of \u03b2-Amyloid Induced Morbific Events","volume":"9","author":"Mohamed Asik","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.brainres.2025.150047_b1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2024.115242","article-title":"Emerging targets in amyotrophic lateral sclerosis (ALS): The promise of ATP-binding cassette (ABC) transporter modulation","volume":"476","author":"Mohan","year":"2025","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.brainres.2025.150047_b1185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40478-017-0488-7","article-title":"What is the evidence that tau pathology spreads through prion-like propagation?","volume":"5","author":"Mudher","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b1190","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00533","article-title":"Nerve Growth Factor Pathobiology During the Progression of Alzheimer\u2019s Disease","volume":"13","author":"Mufson","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1195","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/17512433.2022.2097905","article-title":"Current status and prospects of IL-6\u2013targeting therapy","volume":"15","author":"Narazaki","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.brainres.2025.150047_b1200","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40035-022-00326-w","article-title":"Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules","volume":"11","author":"Natale","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b1205","doi-asserted-by":"crossref","first-page":"12050","DOI":"10.1038\/s41598-018-30487-6","article-title":"IL-1\u03b2, IL-6, TNF- \u03b1 and CRP in Elderly Patients with Depression or Alzheimer\u2019s disease: Systematic Review and Meta-Analysis","volume":"8","author":"Ng","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b1210","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11011-020-00591-6","article-title":"Recent advances in tau-directed immunotherapy against Alzheimer\u2019s disease: an overview of pre-clinical and clinical development","volume":"35","author":"Ng","year":"2020","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1215","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/agm2.12222","article-title":"Chinese expert consensus on assessment of cognitive impairment in the elderly","volume":"5","author":"Ni","year":"2022","journal-title":"Aging Med."},{"key":"10.1016\/j.brainres.2025.150047_b1220","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/17425247.2020.1781088","article-title":"Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets","volume":"17","author":"Niamsuphap","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.brainres.2025.150047_b1225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/biomedicines13010097","article-title":"Affordable mRNA Novel Proteins, Recombinant Protein Conversions, and Biosimilars\u2014Advice to Developers and Regulatory Agencies","volume":"13","author":"Niazi","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.brainres.2025.150047_b1235","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00401-014-1371-2","article-title":"Tau aggregation and its interplay with amyloid-\u03b2","volume":"129","author":"Nisbet","year":"2015","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.brainres.2025.150047_b1245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b1250","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/life13030647","article-title":"Neurotrophins and Other Growth Factors in the Pathogenesis of Alzheimer\u2019s Disease","volume":"13","author":"Numakawa","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.brainres.2025.150047_b1255","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/biomedicines9050524","article-title":"Neuroinflammation in Alzheimer\u2019s Disease","volume":"9","author":"Onyango","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.brainres.2025.150047_b1260","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.brainres.2025.150047_b1265","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12974-021-02332-7","article-title":"Biologic TNF-\u03b1 inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy","volume":"18","author":"Ou","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainres.2025.150047_b1270","first-page":"S41","article-title":"Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies","volume":"19","author":"Owens","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.brainres.2025.150047_b1275","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.brainres.2025.150047_b1280","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jalz.2018.08.008","article-title":"Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study","volume":"15","author":"Palta","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b1285","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1459025","article-title":"The role of PI3K signaling pathway in Alzheimer\u2019s disease","volume":"16","author":"Pan","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1290","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2014.883921","article-title":"Amyloid-based immunotherapy for Alzheimer\u2019s disease in the time of prevention trials: the way forward","volume":"10","author":"Panza","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b1295","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/imt-2016-0019","article-title":"Tau-Based Therapeutics for Alzheimer\u2019s Disease: Active and Passive Immunotherapy","volume":"8","author":"Panza","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.brainres.2025.150047_b1300","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2023.1227816","article-title":"Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier","volume":"3","author":"Pardridge","year":"2023","journal-title":"Front. Drug Deliv."},{"key":"10.1016\/j.brainres.2025.150047_b1305","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jcyt.2019.04.054","article-title":"Adalimumab improves cognitive impairment, exerts neuroprotective effects and attenuates neuroinflammation in an A\u03b21-40-injected mouse model of Alzheimer\u2019s disease","volume":"21","author":"Park","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.brainres.2025.150047_b1310","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41580-024-00753-9","article-title":"Cellular and pathological functions of tau","volume":"25","author":"Parra Bravo","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.brainres.2025.150047_b1315","doi-asserted-by":"crossref","first-page":"13954","DOI":"10.3390\/ijms232213954","article-title":"Alzheimer\u2019s Disease: Treatment Strategies and Their Limitations","volume":"23","author":"Passeri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1320","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3390\/cells10071812","article-title":"The Complement System: A Powerful Modulator and Effector of Astrocyte Function in the Healthy and Diseased Central Nervous System","volume":"10","author":"Pekna","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.150047_b1325","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/s41380-022-01565-z","article-title":"The synapse as a treatment avenue for Alzheimer\u2019s Disease","volume":"27","author":"Peng","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.brainres.2025.150047_b1330","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3390\/molecules25071659","article-title":"Oligomerization and Conformational Change Turn Monomeric \u03b2-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer\u2019s Pathogenesis","volume":"25","author":"Penke","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.brainres.2025.150047_b1335","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/cancers17020298","article-title":"Deciphering the Blood\u2013Brain Barrier Paradox in Brain Metastasis Development and Therapy","volume":"17","author":"Peters","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.brainres.2025.150047_b1340","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/1567205016666190321163438","article-title":"Therapeutic Strategies Targeting Amyloid-\u03b2 in Alzheimer\u2019s Disease","volume":"16","author":"Pinheiro","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainres.2025.150047_b1345","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/ijms24010778","article-title":"Apoe4 and Alzheimer\u2019s Disease Pathogenesis\u2014Mitochondrial Deregulation and Targeted Therapeutic Strategies","volume":"24","author":"Pires","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1350","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-cellbio-100617-062527","article-title":"Sortase A: A Model for Transpeptidation and Its Biological Applications","volume":"34","author":"Pishesha","year":"2018","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.brainres.2025.150047_b1355","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/bcpt.14055","article-title":"Drugs targeting APOE4 that regulate beta-amyloid aggregation in the brain: Therapeutic potential for Alzheimer\u2019s disease","volume":"135","author":"Poblano","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.brainres.2025.150047_b1360","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110020","article-title":"Microglia and TREM2","volume":"257","author":"Pocock","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2025.150047_b1365","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/antib7020019","article-title":"Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity","volume":"7","author":"Pratt","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.brainres.2025.150047_b1370","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12974-020-01915-0","article-title":"Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition","volume":"17","author":"Price","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainres.2025.150047_b1375","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nn.4475","article-title":"The role of peripheral immune cells in the CNS in steady state and disease","volume":"20","author":"Prinz","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1380","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","volume":"21","author":"Pr\u00fcss","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b1385","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/ijms22063048","article-title":"In Translation: FcRn across the Therapeutic Spectrum","volume":"22","author":"Qi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1390","doi-asserted-by":"crossref","first-page":"11374","DOI":"10.1021\/acs.jpcb.1c05997","article-title":"Secondary Structure and Conformational Stability of the Antigen Residues Making Contact with Antibodies","volume":"125","author":"Qiao","year":"2021","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.brainres.2025.150047_b1395","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1169499","article-title":"Safety and efficacy of lecanemab for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials","volume":"15","author":"Qiao","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845897","article-title":"The Specific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer\u2019s Disease","volume":"13","author":"Qin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b1405","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1007\/s12035-024-04449-1","article-title":"Apolipoprotein E in Alzheimer\u2019s Disease: Focus on Synaptic Function and Therapeutic Strategy","volume":"62","author":"Qu","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b1410","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3390\/genes12121959","article-title":"Advances in Genetics and Epigenetic Alterations in Alzheimer\u2019s Disease: A Notion for Therapeutic Treatment","volume":"12","author":"Rabaneda-Bueno","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.brainres.2025.150047_b1415","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3\u201345 Study: Design of a prevention trial for Alzheimer\u2019s disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"10.1016\/j.brainres.2025.150047_b1420","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1007\/s12033-024-01270-y","article-title":"Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges","volume":"67","author":"Raja","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.brainres.2025.150047_b1425","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer\u2019s disease Neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1430","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.3390\/ijms23179604","article-title":"Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review","volume":"23","author":"Ramdani","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1435","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103877","article-title":"Current and emerging strategies for subcutaneous delivery of high-concentration and high-dose antibody therapeutics","volume":"114","author":"Ren","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1440","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b1445","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s13311-022-01283-y","article-title":"A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer\u2019s Disease Mice","volume":"19","author":"Rofo","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.brainres.2025.150047_b1450","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/19420862.2015.1081323","article-title":"The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1\u03b2","volume":"7","author":"Rondeau","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.brainres.2025.150047_b1455","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00280","article-title":"Fc\u03b3 Receptor Heterogeneity in Leukocyte Functional Responses","volume":"8","author":"Rosales","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b1460","first-page":"138","article-title":"Blood-Brain Barrier Permeability in Aging and Alzheimer\u2019s Disease","volume":"1","author":"Rosenberg","year":"2014","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1465","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/biom11081131","article-title":"Transportation of Single-Domain Antibodies through the Blood\u2013Brain Barrier","volume":"11","author":"Ruiz-L\u00f3pez","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.brainres.2025.150047_b1470","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","article-title":"ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease","volume":"17","author":"Safieh","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.brainres.2025.150047_b1480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b1485","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b1490","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70293","article-title":"TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer\u2019s disease","volume":"21","author":"Salloway","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b1495","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","article-title":"Nanobody: outstanding features for diagnostic and therapeutic applications","volume":"411","author":"Salvador","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.brainres.2025.150047_b1500","first-page":"3558","article-title":"Emerging roles for ITAM and ITIM receptor signaling in microglial biology and Alzheimer\u2019s disease-related amyloidosis","volume":"168","author":"Samuels","year":"2024","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2025.150047_b1505","doi-asserted-by":"crossref","unstructured":"Sang, Z., 2025. Chapter 35 - Lecanemab (Leqembi): an amyloid beta monoclonal antibody approved for the treatment of Alzheimer\u2019s disease, in: Yu, B., Zhan, P. (Eds.), Drug Discovery Stories. Elsevier, pp. 647\u2013652. Doi: 10.1016\/B978-0-443-23932-8.00035-2.","DOI":"10.1016\/B978-0-443-23932-8.00035-2"},{"key":"10.1016\/j.brainres.2025.150047_b1510","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1172\/JCI90606","article-title":"Microglia in Alzheimer\u2019s disease","volume":"127","author":"Sarlus","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.brainres.2025.150047_b1515","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/brainsci10040232","article-title":"Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review","volume":"10","author":"Schaffert","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1520","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12974-020-02024-8","article-title":"The good, the bad, and the opportunities of the complement system in neurodegenerative disease","volume":"17","author":"Schartz","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainres.2025.150047_b1525","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/ATVBAHA.120.311911","article-title":"Vascular Hypothesis of Alzheimer Disease","volume":"41","author":"Scheffer","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.brainres.2025.150047_b1530","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s43587-023-00400-6","article-title":"The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer\u2019s disease diagnostic revolution","volume":"3","author":"Schindler","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.brainres.2025.150047_b1540","doi-asserted-by":"crossref","DOI":"10.1002\/alz.057320","article-title":"The design of Dominantly Inherited Alzheimer Disease Trial of the anti-tau antibody, E-2814, on the DIAN-TU Tau Next Generation Platform","volume":"17","author":"Schneider","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b1545","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/biomedicines12051096","article-title":"Passive Anti-Amyloid Beta Immunotherapies in Alzheimer\u2019s Disease: From Mechanisms to Therapeutic Impact","volume":"12","author":"Schreiner","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.brainres.2025.150047_b1550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.958273","article-title":"C1q as a target molecule to treat human disease: What do mouse studies teach us?","volume":"13","author":"Schulz","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b1555","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/jnt4040020","article-title":"Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery","volume":"4","author":"Schwinghamer","year":"2023","journal-title":"J. Nanotheranostics"},{"key":"10.1016\/j.brainres.2025.150047_b1560","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/biophysica1020011","article-title":"Amyloid-mediated mechanisms of membrane disruption","volume":"1","author":"Sciacca","year":"2021","journal-title":"Biophysica"},{"key":"10.1016\/j.brainres.2025.150047_b1565","doi-asserted-by":"crossref","first-page":"13428","DOI":"10.3390\/ijms232113428","article-title":"Molecular Mechanisms of Inhibition of Protein Amyloid Fibril Formation: Evidence and Perspectives Based on Kinetic Models","volume":"23","author":"Sedov","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1570","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100214","article-title":"Bispecific brain-penetrant antibodies for treatment of Alzheimer\u2019s disease","volume":"12","author":"Sehlin","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00302","article-title":"The Structural Basis of Antibody-Antigen Recognition","volume":"4","author":"Sela-Culang","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b1580","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.brainres.2025.150047_b1585","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/jcbfm.2009.240","article-title":"Role of Chemokines in CNS Health and Pathology: A Focus on the CCL2\/CCR2 and CXCL8\/CXCR2 Networks","volume":"30","author":"Semple","year":"2010","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.brainres.2025.150047_b1595","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s11064-023-04085-6","article-title":"The Role of IL-6 in Neurodegenerative Disorders","volume":"49","author":"Shan","year":"2024","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.brainres.2025.150047_b1600","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/0125899775298987240528050110","article-title":"Arbutin\u2019s Potential in Neuroprotection: A Promising Role in Mitigating Neurodegenerative Diseases","volume":"17","author":"Sharma","year":"2025","journal-title":"Curr. Drug Res. Rev."},{"key":"10.1016\/j.brainres.2025.150047_b1605","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/0115734013307906240407093309","article-title":"Unraveling the Anti-Obesity Potential of Luteolin: Mechanistic Insights","volume":"21","author":"Sharma","year":"2025","journal-title":"Curr. Nutr. Food Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1610","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11011-025-01623-9","article-title":"A second act for spironolactone: cognitive benefits in renal dysfunction \u2013 a critical review","volume":"40","author":"Sharma","year":"2025","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1615","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2025.104023","article-title":"Rethinking Parkinson\u2019s: The role of proteostasis networks and autophagy in disease progression","volume":"134","author":"Sharma","year":"2025","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1620","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11011-025-01642-6","article-title":"Unraveling novel mechanisms of ATP-Binding cassette (ABC) transporter in insulin Resistance-induced amyloidogenesis","volume":"40","author":"Sharma","year":"2025","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1625","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40495-023-00327-x","article-title":"Pharmacokinetics and Pharmacodynamics of Neonatal Fc Receptor (FcRn)-Targeting Therapeutic Proteins: a Systemic Review","volume":"9","author":"Sharma","year":"2023","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b1630","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11033-025-10980-8","article-title":"Exploring LRP-1 in the liver-brain axis: implications for Alzheimer\u2019s disease","volume":"52","author":"Sharma","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b1635","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s11064-022-03546-8","article-title":"Kynurenine Metabolism and Alzheimer\u2019s Disease: The Potential Targets and Approaches","volume":"47","author":"Sharma","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.brainres.2025.150047_b1640","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b1645","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/biophysica2020010","article-title":"Amyloid-\u03b2 Oligomers: Multiple Moving Targets","volume":"2","author":"Shea","year":"2022","journal-title":"Biophysica"},{"key":"10.1016\/j.brainres.2025.150047_b1650","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/10738584241254118","article-title":"Microglia, Trem2, and Neurodegeneration","volume":"31","author":"Shi","year":"2025","journal-title":"The Neuroscientist"},{"key":"10.1016\/j.brainres.2025.150047_b1655","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.brainres.2025.150047_b1660","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1426656","article-title":"Single-domain antibodies and aptamers drive new opportunities for neurodegenerative disease research","volume":"15","author":"Shoemaker","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b1665","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","article-title":"TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease","volume":"3","author":"Shulman","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.brainres.2025.150047_b1670","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.3233\/JAD-231238","article-title":"Tau Immunotherapies for Alzheimer\u2019s Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies","volume":"101","author":"Sigurdsson","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.brainres.2025.150047_b1675","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3390\/ijms23042011","article-title":"Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?","volume":"23","author":"Silvestro","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1680","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.imbio.2007.04.001","article-title":"C1q binding and complement activation by prions and amyloids","volume":"212","author":"Sim","year":"2007","journal-title":"Immunobiology"},{"key":"10.1016\/j.brainres.2025.150047_b1685","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.3390\/jcm12216792","article-title":"Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA","volume":"12","author":"Sin","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.brainres.2025.150047_b1690","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1871527317666180627122448","article-title":"Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?","volume":"17","author":"Singh","year":"2018","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.brainres.2025.150047_b1695","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.3390\/ijms25136901","article-title":"Comprehensive Overview of Alzheimer\u2019s Disease: Etiological Insights and Degradation Strategies","volume":"25","author":"Singh","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1700","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01208","article-title":"Targeted Intracellular Delivery of Antibodies: The State of the Art","volume":"9","author":"Slastnikova","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainres.2025.150047_b1710","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4356386","article-title":"Oxidative Stress-Mediated Blood-Brain Barrier (BBB) Disruption in Neurological Diseases","volume":"2020","author":"Song","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.brainres.2025.150047_b1715","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/biomedicines9020190","article-title":"Critical Molecular and Cellular Contributors to Tau Pathology","volume":"9","author":"Song","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.brainres.2025.150047_b1720","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1742-2094-9-219","article-title":"Low-level laser therapy regulates microglial function through Src-mediated signaling pathways: implications for neurodegenerative diseases","volume":"9","author":"Song","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainres.2025.150047_b1730","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00016","article-title":"Protein phosphatase 2A dysfunction in Alzheimer\u2019s disease","volume":"7","author":"Sontag","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1735","doi-asserted-by":"crossref","unstructured":"Spencer, B., Rissman, R.A., Overk, C., Masliah, E., 2022. Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimer\u2019s Disease and Related Dementias, in: Langel, \u00dc. (Ed.), Cell Penetrating Peptides: Methods and Protocols. Springer US, New York, NY, pp. 447\u2013457. Doi: 10.1007\/978-1-0716-1752-6_28.","DOI":"10.1007\/978-1-0716-1752-6_28"},{"key":"10.1016\/j.brainres.2025.150047_b1740","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of Solanezumab in Preclinical Alzheimer\u2019s Disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.brainres.2025.150047_b1745","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 Study: Stopping AD Before Symptoms Begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2025.150047_b1750","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi8593","article-title":"Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q","volume":"14","author":"Spurrier","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2025.150047_b1755","unstructured":"staceywhite, 2025. TargetTau-1: A Phase II Trial Evaluating the Efficacy, Safety, and Tolerability of a Monoclonal Antibody Targeting the Tau Protein Microtubule Binding Region in Patients with Early Alzheimer\u2019s Disease."},{"key":"10.1016\/j.brainres.2025.150047_b1760","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/14728222.2023.2177532","article-title":"The case for complement component 5 as a target in neurodegenerative disease","volume":"27","author":"Stennett","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.brainres.2025.150047_b1765","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.trci.2018.10.006","article-title":"Alzheimer\u2019s disease in Down syndrome: An overlooked population for prevention trials","volume":"4","author":"Strydom","year":"2018","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.brainres.2025.150047_b1770","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3390\/molecules27061776","article-title":"Amyloid Cross-Seeding: Mechanism, Implication, and Inhibition","volume":"27","author":"Subedi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.brainres.2025.150047_b1775","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00319","article-title":"Alzheimer\u2019s Disease: From Genetic Variants to the Distinct Pathological Mechanisms","volume":"10","author":"Sun","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1780","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-022-01273-8","article-title":"Fc effector of anti-A\u03b2 antibody induces synapse loss and cognitive deficits in Alzheimer\u2019s disease-like mouse model","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b1785","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-Brain Barrier: From Physiology to Disease and Back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.brainres.2025.150047_b1795","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1038\/ncomms9490","article-title":"Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer\u2019s disease brain","volume":"6","author":"Takeda","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b1800","article-title":"Lecanemab for mild Alzheimer disease \u2013 is there a way forward? Drugs","volume":"14","author":"Tampi","year":"2025","journal-title":"Context"},{"key":"10.1016\/j.brainres.2025.150047_b1805","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1038\/s41467-025-58746-x","article-title":"Allosteric targeted drug delivery for enhanced blood-brain barrier penetration via mimicking transmembrane domain interactions","volume":"16","author":"Tang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b1810","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.trci.2018.02.002","volume":"4","author":"Tariot","year":"2018","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.brainres.2025.150047_b1820","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1517\/14712598.2013.789856","article-title":"Bapineuzumab and solanezumab for Alzheimer\u2019s disease: is the \u201camyloid cascade hypothesis\u201d still alive?","volume":"13","author":"Tayeb","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b1825","article-title":"Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes","volume":"6","author":"Taylor","year":"2020","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.brainres.2025.150047_b1830","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b1835","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41582-025-01073-y","article-title":"Knowing the enemy: strategic targeting of complement to treat Alzheimer disease","volume":"21","author":"Tenner","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b1840","doi-asserted-by":"crossref","first-page":"25272","DOI":"10.1073\/pnas.2002956117","article-title":"The role of fibril structure and surface hydrophobicity in secondary nucleation of amyloid fibrils","volume":"117","author":"Thacker","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","article-title":"Neuroinflammation in Alzheimer\u2019s Disease: current Progress in Molecular Signaling and Therapeutics","volume":"46","author":"Thakur","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.brainres.2025.150047_b1850","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14737175.2024.2402058","article-title":"Profiling aducanumab as a treatment option for Alzheimer\u2019s disease: an overview of efficacy, safety and tolerability","volume":"24","author":"Thussu","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.brainres.2025.150047_b1855","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1007\/s12035-018-1237-z","article-title":"APOE and Alzheimer\u2019s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer\u2019s Pathogenesis","volume":"56","author":"Uddin","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b1860","first-page":"43","article-title":"Molecular Genetics of Early- and Late-Onset Alzheimer\u2019s Disease","volume":"21","author":"Uddin","year":"2021","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.brainres.2025.150047_b1865","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.3390\/ijms21165858","article-title":"Revisiting the Amyloid Cascade Hypothesis: From Anti-A\u03b2 Therapeutics to Auspicious New Ways for Alzheimer\u2019s Disease","volume":"21","author":"Uddin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1870","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","article-title":"TREM2 \u2014 a key player in microglial biology and Alzheimer disease","volume":"14","author":"Ulland","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b1875","doi-asserted-by":"crossref","first-page":"39374","DOI":"10.1038\/srep39374","article-title":"Structure of Crenezumab Complex with A\u03b2 Shows Loss of \u03b2-Hairpin","volume":"6","author":"Ultsch","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b1880","first-page":"416","article-title":"A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer\u2019s disease models","volume":"26","author":"van Lengerich","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1885","series-title":"Advances in the Management of Early Alzheimer\u2019s Disease","first-page":"51","article-title":"Chapter 4 - The need for early diagnosis\u2014Clinical, societal and health economic drivers","author":"van Maurik","year":"2025"},{"key":"10.1016\/j.brainres.2025.150047_b1890","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/psc.573","article-title":"Amyloid \u03b2-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer\u2019s disease","volume":"10","author":"Verdier","year":"2004","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1895","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00259-023-06177-5","article-title":"FDA approval of lecanemab: the real start of widespread amyloid PET use? \u2014 the EANM Neuroimaging Committee perspective","volume":"50","author":"Verger","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.brainres.2025.150047_b1900","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","article-title":"Lecanemab (BAN2401): an anti\u2013beta-amyloid monoclonal antibody for the treatment of Alzheimer disease","volume":"32","author":"Vitek","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.brainres.2025.150047_b1905","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00018-021-04090-4","article-title":"Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing","volume":"79","author":"Vit\u00f3ria","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1910","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40478-019-0754-y","article-title":"Intersection of pathological tau and microglia at the synapse","volume":"7","author":"Vogels","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b1915","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1159\/000542666","article-title":"The Impact of Vascular Risk Factors on Cerebral Amyloid Angiopathy: A Cohort Study in Hereditary Cerebral Amyloid Angiopathy and a Systemic Review in Sporadic Cerebral Amyloid Angiopathy","volume":"54","author":"Voigt","year":"2025","journal-title":"Cerebrovasc. Dis. Basel Switz."},{"key":"10.1016\/j.brainres.2025.150047_b1920","doi-asserted-by":"crossref","first-page":"12246","DOI":"10.3390\/ijms241512246","article-title":"The Amyloid Cascade Hypothesis 2.0 for Alzheimer\u2019s Disease and Aging-Associated Cognitive Decline: From Molecular Basis to Effective Therapy","volume":"24","author":"Volloch","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1925","unstructured":"Walker, L.C., n.d. A\u03b2 plaques. Free Neuropathol. 1, 31. Doi: 10.17879\/freeneuropathology-2020-3025."},{"key":"10.1016\/j.brainres.2025.150047_b1930","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","article-title":"UB-311, a novel UBITh\u00ae amyloid \u03b2 peptide vaccine for mild Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.brainres.2025.150047_b1935","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2021.773590","article-title":"Microglia Heterogeneity in Alzheimer\u2019s Disease: Insights From Single-Cell Technologies","volume":"13","author":"Wang","year":"2021","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1945","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and Production of Bispecific Antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.brainres.2025.150047_b1950","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","article-title":"Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances","volume":"15","author":"Wang","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b1955","first-page":"136","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.brainres.2025.150047_b1965","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b1970","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.bbi.2010.05.010","article-title":"Intramuscular delivery of a single chain antibody gene prevents brain A\u03b2 deposition and cognitive impairment in a mouse model of Alzheimer\u2019s disease","volume":"24","author":"Wang","year":"2010","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.brainres.2025.150047_b1975","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cns.14129","article-title":"Association of rs2062323 in the TREM1 gene with Alzheimer\u2019s disease and cerebrospinal fluid-soluble TREM2","volume":"29","author":"Wang","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b1980","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to Generate Antibody-Based Therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b1985","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/alz.12789","article-title":"Alzheimer\u2019s disease as an innate autoimmune disease (AD2): A new molecular paradigm","volume":"19","author":"Weaver","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2025.150047_b1990","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s00415-021-10573-y","article-title":"The propagation mechanisms of extracellular tau in Alzheimer\u2019s disease","volume":"269","author":"Wei","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b1995","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s40478-019-0770-y","article-title":"Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans","volume":"7","author":"Weisov\u00e1","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b2000","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200127","article-title":"Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings","volume":"13","author":"Wessels","year":"2023","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.brainres.2025.150047_b2005","first-page":"236","article-title":"Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer\u2019s Disease and Other Tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2025.150047_b2010","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/antib4030170","article-title":"Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases","volume":"4","author":"Westwood","year":"2015","journal-title":"Antibodies"},{"key":"10.1016\/j.brainres.2025.150047_b2015","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40120-024-00664-z","article-title":"Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years","volume":"13","author":"Wicker","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b2020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia\u2013Evidence for Amyloid Scanning (IDEAS) Cohort Study","volume":"79","author":"Wilkins","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.brainres.2025.150047_b2025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13024-020-0358-9","article-title":"Therapeutic approaches targeting Apolipoprotein E function in Alzheimer\u2019s disease","volume":"15","author":"Williams","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b2030","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrn3983","article-title":"A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome","volume":"16","author":"Wiseman","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b2035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jech-2016-207809","article-title":"Associations between specific autoimmune diseases and subsequent dementia: retrospective record-linkage cohort study, UK","volume":"71","author":"Wotton","year":"2017","journal-title":"J. Epidemiol. Commun. Health"},{"key":"10.1016\/j.brainres.2025.150047_b2040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12987-020-00226-z","article-title":"Identification and in vivo characterization of a brain-penetrating nanobody","volume":"17","author":"Wouters","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.brainres.2025.150047_b2045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: Structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b2050","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.2147\/IJN.S520768","article-title":"Brain Delivery Strategies for Biomacromolecular Drugs: Intranasal Administration","volume":"20","author":"Wu","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.brainres.2025.150047_b2055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40035-021-00270-1","article-title":"The role of pathological tau in synaptic dysfunction in Alzheimer\u2019s diseases","volume":"10","author":"Wu","year":"2021","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b2060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-021-00460-5","article-title":"\u201cDon\u2019t Phos Over Tau\u201d: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer\u2019s disease and other tauopathies","volume":"16","author":"Xia","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2025.150047_b2065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s12640-018-9895-1","article-title":"Clearance of Amyloid Beta and Tau in Alzheimer\u2019s Disease: from Mechanisms to Therapy","volume":"34","author":"Xin","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.brainres.2025.150047_b2070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd7522","article-title":"APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function","volume":"13","author":"Xiong","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2025.150047_b2075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/ITT.S455881","article-title":"Advances in the Understanding of the Correlation Between Neuroinflammation and Microglia in Alzheimer\u2019s Disease","volume":"13","author":"Yan","year":"2024","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.brainres.2025.150047_b2080","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/ijms22031244","article-title":"APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer\u2019s","volume":"22","author":"Yang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b2085","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jpsychires.2022.09.052","article-title":"Association of autoimmune diseases with Alzheimer\u2019s disease: A mendelian randomization study","volume":"155","author":"Yeung","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.brainres.2025.150047_b2090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13195-020-0580-2","article-title":"Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer\u2019s disease","volume":"12","author":"Yoshida","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b2095","doi-asserted-by":"crossref","unstructured":"Yu, H.J., Dickson, S.P., Wang, P.-N., Chiu, M.-J., Huang, C.-C., Chang, C.-C., Liu, H., Hendrix, S.B., Dodart, J.-C., Verma, A., Wang, C.Y., Cummings, J., 2023. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 2a study. eBioMedicine 94. Doi: 10.1016\/j.ebiom.2023.104665.","DOI":"10.1016\/j.ebiom.2023.104665"},{"key":"10.1016\/j.brainres.2025.150047_b2100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/imr.13381","article-title":"Single domain antibody: Development and application in biotechnology and biopharma","volume":"328","author":"Yu","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.brainres.2025.150047_b2105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/1673-5374.374138","article-title":"Are TrkB receptor agonists the right tool to fulfill the promises for a therapeutic value of the brain-derived neurotrophic factor?","volume":"19","author":"Zagrebelsky","year":"2024","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.brainres.2025.150047_b2110","first-page":"23","article-title":"Immunotherapy Targeting Amyloid-\u03b2 Peptides in Alzheimer\u2019s Disease","author":"Zampar","year":"2020","journal-title":"Exon Publ."},{"key":"10.1016\/j.brainres.2025.150047_b2115","doi-asserted-by":"crossref","DOI":"10.1098\/rsfs.2017.0030","article-title":"Factors affecting the physical stability (aggregation) of peptide therapeutics","volume":"7","author":"Zapadka","year":"2017","journal-title":"Interface Focus"},{"key":"10.1016\/j.brainres.2025.150047_b2120","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jocn.2011.12.022","article-title":"Roles of brain-derived neurotrophic factor\/tropomyosin-related kinase B (BDNF\/TrkB) signalling in Alzheimer\u2019s disease","volume":"19","author":"Zhang","year":"2012","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b2125","article-title":"Role of A\u03b2 in Alzheimer\u2019s-related synaptic dysfunction","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.brainres.2025.150047_b2130","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Interaction between A\u03b2 and Tau in the Pathogenesis of Alzheimer\u2019s Disease","volume":"17","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.brainres.2025.150047_b2135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b2140","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.2147\/JIR.S483412","article-title":"Prevention and Treatment Strategies for Alzheimer\u2019s Disease: Focusing on Microglia and Astrocytes in Neuroinflammation","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.brainres.2025.150047_b2145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b2150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b2155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-6606-4-3","article-title":"APP processing in Alzheimer\u2019s disease","volume":"4","author":"Zhang","year":"2011","journal-title":"Mol. Brain"},{"key":"10.1016\/j.brainres.2025.150047_b2165","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1007\/s11064-020-03121-z","article-title":"Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer\u2019s Disease","volume":"45","author":"Zhang","year":"2020","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.brainres.2025.150047_b2170","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00339","article-title":"Cellular Prion Protein as a Receptor of Toxic Amyloid-\u03b242 Oligomers Is Important for Alzheimer\u2019s Disease","volume":"13","author":"Zhang","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.brainres.2025.150047_b2180","doi-asserted-by":"crossref","unstructured":"Zhao, P., Xu, Y., Fan, X., Li, L., Li, X., Arase, H., Tong, Q., Zhang, N., An, Z., 2022a. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. mAbs 14, 2107971. Doi: 10.1080\/19420862.2022.2107971.","DOI":"10.1080\/19420862.2022.2107971"},{"key":"10.1016\/j.brainres.2025.150047_b2185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq0095","article-title":"A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer\u2019s disease","volume":"14","author":"Zhao","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2025.150047_b2190","first-page":"311","article-title":"Engineering antibody and protein therapeutics to cross the blood\u2013brain barrier","volume":"5","author":"Zhao","year":"2022","journal-title":"Antib. Ther."},{"key":"10.1016\/j.brainres.2025.150047_b2195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978513","article-title":"Applications of nanobodies in brain diseases","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.brainres.2025.150047_b2200","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1007\/s12035-021-02293-1","article-title":"Infliximab Can Improve Traumatic Brain Injury by Suppressing the Tumor Necrosis Factor Alpha Pathway","volume":"58","author":"Zhou","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.brainres.2025.150047_b2205","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc7031","article-title":"Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy","volume":"6","author":"Zhou","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.brainres.2025.150047_b2210","doi-asserted-by":"crossref","first-page":"13701","DOI":"10.1021\/acs.chemrev.1c00308","article-title":"Protein Assembly by Design","volume":"121","author":"Zhu","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.brainres.2025.150047_b2215","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70802","article-title":"Recent Advancements in Neuroimaging-Based Alzheimer\u2019s Disease Prediction Using Deep Learning Approaches in e-Health: A Systematic Review","volume":"8","author":"Zia-Ur-Rehman","year":"2025","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.brainres.2025.150047_b2220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1742-2094-9-47","article-title":"Who fans the flames of Alzheimer\u2019s disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways","volume":"9","author":"Zilka","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainres.2025.150047_b2225","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40478-020-00948-z","article-title":"Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation","volume":"8","author":"Zilkova","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.brainres.2025.150047_b2230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/fhep-2014-0013","article-title":"The Value of Delaying Alzheimer\u2019s Disease Onset","volume":"18","author":"Zissimopoulos","year":"2015","journal-title":"Forum Health Econ. Policy"}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325006109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325006109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:26:09Z","timestamp":1775147169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899325006109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":430,"alternative-id":["S0006899325006109"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2025.150047","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2025.150047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150047"}}